ClinicalTrials.gg
CompletedNCT05312151Updated Jun 13, 2025Results posted

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

A Phase 2 interventional study of Psilocybin in Post Traumatic Stress Disorder, sponsored by COMPASS Pathways. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by COMPASS Pathways · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Enrollment
13th of 20
22 · median 33
Started
2022
with 2 others
Phase 2
10 of 20
5 open now
Registered
4th of 20
by date
Lead sponsor
2 of 20
COMPASS Pathways

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 13th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, and was the 4th registered.

Stress Disorders, Post-Traumatic

2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder

Read the detailed description

The Safety and Tolerability of COMP360 administered under supportive conditions in participants with Post-traumatic Stress Disorder

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • psilocybin
  • COMP360
  • COMPASS
  • PTSD
  • Post Traumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Meet criteria for current PTSD resulting from a trauma experienced during adulthood measured via the PCL-5 in combination with the LEC-5 at screening
  • Meet DSM-5 criteria for current PTSD resulting from a trauma experienced during adulthood as assessed by the CAPS, with a minimum score of 25 at baseline
  • Able to identify a next of kin who is willing and able to be reached by the investigators in case of emergency
  • Have successfully discontinued all prohibited medications at least two weeks prior to baseline visit. For fluoxetine (Prozac), immediate cessation at screening period visit 1a followed by at least four weeks of run-in will be required prior to baseline

Key Exclusion Criteria:

  • Current or past history of schizophrenia, schizoaffective disorder or any other form of psychotic disorder, obsessive compulsive disorder, personality disorders, bipolar disorder, or any other significant disorder as assessed by clinician judgement and a structured clinical interview (MINI 7.0.2)
  • Diagnosis of complex PTSD according to clinician judgement
  • Borderline Personality Disorder as demonstrated by both the McLean Screening Instrument for Borderline Personality Disorder (MSI- BPD) score ≥ 7 and clinical confirmation of diagnosis by the study clinician and Medical Monitor
  • Significant suicide risk as defined by (1) suicidal ideation as endorsed on items 4 or 5 on the C-SSRS within the past year, during screening or at baseline, or; (2) suicidal behaviours within the past year, or; (3) history of serious suicide attempt that required a rescuing medical intervention, or; (4) clinical assessment of significant suicidal risk during participant interview
  • Current (within the last year) alcohol or substance use disorder as informed by DSM-5 assessed via the MINI 7.0.2 at screening
  • Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin
  • Exposure to 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide (LSD), or peyote in the past year
  • Primary diagnosis of major depressive disorder within 6 months of study entry
  • Exposure to a traumatic experience in the past 3 months
  • Significant childhood physical or sexual abuse based on clinician judgment with the use of CTQ
  • Enrolment in a psychological therapy programme that will not remain stable for the duration of the study. Psychological therapies cannot have been initiated within 21 days of baseline
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    COMP360 Psilocybin

    25 mg COMP360 Psilocybin

    Drug: Psilocybin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline

    CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity.

    Time frame: Week 12

  2. Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders

    CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as a responder if they have a greater than or equal to 15 point improvement on the CAPS-5 total severity score compared to Baseline.

    Time frame: Week 12

  3. Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.

    CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as remitter at any post-baseline timepoint if their CAPS-5 total severity score is less than or equal to 20.

    Time frame: Week 12

  4. Change in Sheehan Disability Scale (SDS) Total Score From Baseline

    SDS is a 5 item scale. The total score is calculated by summing the 3 domains (work/school, social life, and family life - each domain has a 0-10 range). The total score has a range from 0 to 30, with 0 representing no impairment and 30 representing severe impairment.

    Time frame: Week 12

07

Results

Posted Jun 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneCOMP360 Psilocybin
Started22
Completed22
Not completed0

Outcome measures

PrimaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

A TEAE is defined as an adverse event (AE) that has an onset on or after the dose of study drug, or any pre-existing AE condition that has worsened on or after the dose of study drug.

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsCOMP360 Psilocybin
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)22
SecondaryChange in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline

CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline
units on a scaleCOMP360 Psilocybin
Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score From Baseline-29.5 ± 15.43
SecondaryProportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders

CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as a responder if they have a greater than or equal to 15 point improvement on the CAPS-5 total severity score compared to Baseline.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders
ParticipantsCOMP360 Psilocybin
Proportion of Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Responders17
SecondaryProportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.

CAPS-5 is a 30 item scale, each item is scored from 0-4, total severity score is calculated by taking the sum of the individual item scores (range: 0-80). Higher scores denote greater symptom severity. A participant is defined as remitter at any post-baseline timepoint if their CAPS-5 total severity score is less than or equal to 20.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.
ParticipantsCOMP360 Psilocybin
Proportion of Clinician-Administered PTSD Scale From DSM-5 (CAPS-5) Remitters.12
SecondaryChange in Sheehan Disability Scale (SDS) Total Score From Baseline

SDS is a 5 item scale. The total score is calculated by summing the 3 domains (work/school, social life, and family life - each domain has a 0-10 range). The total score has a range from 0 to 30, with 0 representing no impairment and 30 representing severe impairment.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Change in Sheehan Disability Scale (SDS) Total Score From Baseline
units on a scaleCOMP360 Psilocybin
Change in Sheehan Disability Scale (SDS) Total Score From Baseline-14.4 ± 8.21

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
COMP360 Psilocybin0/22 (0%)0/22 (0%)22/22 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCOMP360 Psilocybin
NauseaGastrointestinal disorders8/22
CryingGeneral disorders6/22
FatigueGeneral disorders6/22
Tension headacheNervous system disorders6/22
HeadacheNervous system disorders6/22
Hallucination, visualPsychiatric disorders5/22
Visual impairmentEye disorders3/22
Muscle tightnessMusculoskeletal and connective tissue disorders3/22
ParaesthesiaNervous system disorders3/22
ChillsGeneral disorders2/22

Baseline characteristics

Safety Analysis Set - all participants who received study drug.

Age, Categorical
Age, Categorical(Participants)COMP360 Psilocybin
<=18 years0
Between 18 and 65 years22
>=65 years0
Age, Continuous
Age, Continuous(years)COMP360 Psilocybin
Mean39.0 ± 7.91
Sex: Female, Male
Sex: Female, Male(Participants)COMP360 Psilocybin
Female14
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)COMP360 Psilocybin
Hispanic or Latino0
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)COMP360 Psilocybin
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)COMP360 Psilocybin
United States9
United Kingdom13
CAPS-5 Total Symptom Severity Score
CAPS-5 Total Symptom Severity Score(units on a scale)COMP360 Psilocybin
Mean47.5 ± 9.78
08

Study locations

3 sites
  • Sunstone Therapies
    Rockville, Maryland 20850, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Kings College London, Institute of Psychiatry, Psychology and Neurology
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Feb 2024, 20 months.

Results were first posted in Jun 2025, 1 year 4 months after primary completion.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 20 months is close to that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Apr 5, 2022
StartActual
Jun 10, 2022
Primary completionActual
Feb 12, 2024
CompletionActual
Feb 12, 2024
Results first posted
Jun 13, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05312151
Lead sponsor
COMPASS Pathways
Responsible party
Sponsor
First posted
Apr 5, 2022
Start date
Jun 10, 2022
Primary completion
Feb 12, 2024
Completion
Feb 12, 2024
Results posted
Jun 13, 2025
Last update
Jun 13, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion